title: Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins.
abstract: BACKGROUND
  Since atherogenesis is related to oxidative stress, our objective was to study the association of oxidative stress markers with the vascular recurrence in non-cardioembolic stroke.
  
  
  METHODS
  Atherosclerotic and oxidative stress markers were evaluated on admission, in 477 patients suffering from a first non-cardioembolic stroke. Patients were followed at 6 and 12 months after inclusion, recording cardiovascular events. As markers of endothelial oxidative stress we used oxidized LDL, Cu/Zn superoxide dismutase and 8-OH deoxiguanosine. 136 patients were being treated with statins at the moment of serum samples acquisition.
  
  
  RESULTS
  Patients who suffered vascular recurrence or vascular-origin death had higher levels of 8-OHDG (40.06 ± 24.70 vs 33.11 ± 15.18;p=0.003). We also found associations between vascular recurrence or vascular origin death and Cu/ZnSOD (OR,1.02; 95%CI,1.00-1.03;p=0.0001) and 8-OHDG (OR,1.12;95%CI,1.08-1.16;p<0.0001) in a subgroup of 333 patients that were not in treatment with statins on admission. We also found associations between 8-OHDG and intima media thickness (IMT) (OR,1.13;95%CI,1.09-1.16;p<0.0001), presence of ipsilatieral stenosis ≥ 50% (OR,1.03;95%CI 1.00-1.05;p=0.007) and other atherosclerotic plaque characteristics.
  
  
  CONCLUSIONS
  Specific oxidative stress markers were found to be markers of atherosclerosis plaque types and vascular recurrence in non-statins treated patients at admission.
authors.affiliation: Clinical Neuroscience Research Laboratory, Department of Neurology, Hospital Clínico Universitario, University of Santiago de Compostela, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Brea
authors.forename: Jaume
authors.initials: J
authors.lastname: Roquer
authors.forename: Joaquín
authors.initials: J
authors.lastname: Serena
authors.forename: Tomás
authors.initials: T
authors.lastname: Segura
authors.forename: José
authors.initials: J
authors.lastname: Castillo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002561:Cerebrovascular Disorders / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology*; D015897:Comorbidity; D004617:Embolism / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D015995:Prevalence; D017382:Reactive Oxygen Species / Q000097:blood*; D012008:Recurrence; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D020521:Stroke / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species